Tego Science, Inc.
Develops and commercializes cell therapies for regenerative medicine.
191420 | KO
Overview
Corporate Details
- ISIN(s):
- KR7191420009
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시
- Website:
- http://www.tegoscience.com/
- Sector:
- Manufacturing
Description
Tego Science, Inc. is a biopharmaceutical company specializing in the development and commercialization of cell therapies for regenerative medicine. The company leverages proprietary, advanced cell culture technology for the mass production of human epithelial cells. Its portfolio of approved products includes Holoderm®, an autologous cultured epidermis for severe burns; Kaloderm®, an allogeneic cell therapy for burns and diabetic foot ulcers; and Rosmir®, an autologous fibroblast treatment for wrinkles. In addition to its therapeutic products, Tego Science provides Neoderm®, a 3D cultured skin model used as an alternative to animal testing, and offers CDMO services. The company's clinical pipeline features TPX-115, a first-in-class allogeneic fibroblast-based therapy for treating rotator cuff tears, currently in late-stage clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-20 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청) (회전근개 부분층 파열 개선위한 TPX115 미국 제 2상 임상시험계획(I…
|
Korean | 8.2 KB | ||
| 2024-12-12 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2024-11-14 00:00 |
분기보고서 (2024.09)
|
Korean | 987.8 KB | ||
| 2024-10-31 00:00 |
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 13.1 KB | ||
| 2024-08-14 00:00 |
반기보고서 (2024.06)
|
Korean | 971.6 KB | ||
| 2024-07-26 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정) (코입술주름 개선 세포치료제 TPX121 제1상 임상시험계획 승인 )
|
Korean | 10.3 KB | ||
| 2024-07-26 00:00 |
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (코입술주름 개선 세포치료제 TPX121 제1상 임상시험계…
|
Korean | 13.6 KB | ||
| 2024-06-28 00:00 |
기타시장안내 (업종변경 안내)
|
Korean | 4.7 KB | ||
| 2024-05-29 00:00 |
주요사항보고서(유형자산양도결정)
|
Korean | 11.3 KB | ||
| 2024-05-21 00:00 |
투자판단관련주요경영사항 (주름개선 세포치료제 로스미르의 식품의약품안전처 허가조건 변경 승인)
|
Korean | 6.7 KB | ||
| 2024-05-14 00:00 |
분기보고서 (2024.03)
|
Korean | 910.8 KB | ||
| 2024-03-27 00:00 |
정기주주총회결과
|
Korean | 19.2 KB | ||
| 2024-03-27 00:00 |
[기재정정]사업보고서 (2023.12)
|
Korean | 1.2 MB | ||
| 2024-03-19 00:00 |
감사보고서제출
|
Korean | 24.5 KB | ||
| 2024-03-19 00:00 |
사업보고서 (2023.12)
|
Korean | 443.8 KB |
Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tego Science, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
